Two‐Year Clinical Trial of Oral Alendronate Versus Intravenous Pamidronate in Children With Osteogenesis Imperfecta

A 2‐year prospective, partially randomized open‐label trial comparing oral alendronate with intravenous pamidronate therapy in children with OI showed equivalence in increasing total body BMD, spine BMD, and linear growth, and decreasing bone turnover and fracture incidence. Children with mild OI had greater responses than severe OI in BMD and growth.

[1]  David Greenblatt,et al.  Treatment of Postmenopausal Osteoporosis , 2005, Pharmacotherapy.

[2]  F. Glorieux,et al.  Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  L. Dimeglio,et al.  Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. , 2004, Bone.

[4]  R. Engelbert,et al.  Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study , 2004, The Lancet.

[5]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[6]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[7]  D. Wenkert,et al.  Bisphosphonate-induced osteopetrosis. , 2003, The New England journal of medicine.

[8]  M. Defontaine,et al.  Assessing the reproducibility of quantitative ultrasound parameters with standardized coefficient of variation or intraclass correlation coefficient: a unique approach , 2003, Osteoporosis International.

[9]  F. Glorieux,et al.  Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. , 2003, Pediatrics.

[10]  F. Glorieux,et al.  Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. , 2003, The Journal of clinical endocrinology and metabolism.

[11]  Marni J. Falk,et al.  Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. , 2003, Pediatrics.

[12]  F. Glorieux,et al.  The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. , 2002, The Journal of clinical investigation.

[13]  S. Söderhäll,et al.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta , 2002, Archives of disease in childhood.

[14]  A. Díez-Pérez,et al.  Two New Single‐Nucleotide Polymorphisms in the COL1A1 Upstream Regulatory Region and Their Relationship to Bone Mineral Density , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  Y. Lee,et al.  Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta , 2001, European Journal of Pediatrics.

[16]  P. Meunier,et al.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. , 2000, Bone.

[17]  F. Glorieux,et al.  Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  W. Greulich,et al.  Radiographic Atlas of Skeletal Development of the Hand and Wrist , 1999 .

[19]  F. Glorieux,et al.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. , 1998, The New England journal of medicine.

[20]  S. Söderhäll,et al.  Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta , 1998, Acta paediatrica.

[21]  G. Massa,et al.  Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate) , 1997, European Journal of Pediatrics.

[22]  C. Paterson.  Osteogenesis imperfecta and other heritable disorders of bone. , 1997, Bailliere's clinical endocrinology and metabolism.

[23]  G. Rodan,et al.  Bisphosphonates: mechanisms of action , 1998, Endocrine reviews.

[24]  J. Lin,et al.  Bisphosphonates: a review of their pharmacokinetic properties. , 1996, Bone.

[25]  J. Kopp,et al.  Changes in apatite crystal size in bones of patients with osteogenesis imperfecta , 1991, Calcified Tissue International.

[26]  J. Tanner,et al.  Clinical longitudinal standards for height and height velocity for North American children. , 1985, The Journal of pediatrics.

[27]  D. Sillence,et al.  Genetic heterogeneity in osteogenesis imperfecta. , 1979, Journal of medical genetics.

[28]  J M Tanner,et al.  Variations in the Pattern of Pubertal Changes in Boys , 1970, Archives of disease in childhood.

[29]  J M Tanner,et al.  Variations in pattern of pubertal changes in girls. , 1969, Archives of disease in childhood.

[30]  L. Dimeglio,et al.  A Comparison of Oral and Intravenous Bisphosphonate Therapy for Children with Osteogenesis Imperfecta , 2005, Journal of pediatric endocrinology & metabolism : JPEM.

[31]  I. Fujiwara,et al.  Intravenous pamidronate treatment in osteogenesis imperfecta. , 1998, European journal of pediatrics.

[32]  Wilton Marion Krogman,et al.  Radiographic Atlas of Skeletal Development of the Hand and Wrist , 1951 .

[33]  P. Esposito,et al.  Osteogenesis Imperfecta. , 1928, Proceedings of the Royal Society of Medicine.